Marshall Wace Asia’s MediciNova MNOV Stock Holding History

Marshall Wace Asia’s Portfolio MNOV Stock Details MNOV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-15,200	Closed	-$56K	–	147
2020 Q1	$56K	Buy	+15,200	New	+$79.1K	﹤0.01%	100

Other funds holding MNOV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Marshall Wace Asia's MNOV Position: Q2 2020 in Review

Marshall Wace Asia sold out of MediciNova (MNOV) in Q2 2020, closing a stake of 15,200 shares — an estimated $56K sold.

Marshall Wace Asia first reported a position in MNOV in Q1 2020 and held it in 1 quarter. The position peaked at $56K in Q1 2020. 50 funds tracked by Wall St. Rank hold MNOV as of Q2 2020.

Marshall Wace Asia reported no remaining MediciNova position as of Q2 2020 after selling out during the quarter.
Marshall Wace Asia sold 15,200 MediciNova shares in Q2 2020, an estimated $56K.
Marshall Wace Asia first reported a position in MediciNova in Q1 2020 and held it in 1 quarter.
Marshall Wace Asia's MediciNova position peaked at $56K in Q1 2020.
50 funds tracked by Wall St. Rank held MediciNova as of Q2 2020.

Based on Marshall Wace Asia's 13F filing for Q2 2020, filed 13 Aug 2020.